All News Mabpharm Limited

Equities

2181

KYG5780F1046

Delayed Hong Kong S.E. Other stock markets 04:08:28 2024-05-20 EDT			5-day change	1st Jan Change
0.375 ^HKD	-3.85%		0.00%	-18.48%

03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-10	Livzon Pharma Recognizes Credit, Asset Impairments	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Livzon Pharma Recognizes Credit, Asset Impairments	01-10	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	12-04	MT
Mabpharm Limited Announces Director Changes	11-28	CI
Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	11-13	AQ
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
China Grants Nod to Livzon Pharmaceutical Subsidiary's Clinical Trials for SARS-CoV-2 Booster Shot	23-07-16	MT
Livzon Pharma Raises Cap in Extended Purchase Agreement to 39 Million Yuan	23-07-03	MT
China Gives New Drug Application Approval to Mabpharm's Anti-Asthma Therapy	23-05-23	MT
Mabpharm Grants Jemincare Pharma Unit Promotion Rights to Asthma Drug	23-04-13	MT
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Chinese Regulator Accepts Mabpharm's New Drug Application for Colorectal Cancer Treatment	23-03-14	MT
Mabpharm Limited Announces New Drug Application of CMAB009	23-03-14	CI
Livzon Pharma's COVID vaccine gets approval as booster in China	22-09-02	RE
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
China Approves Clinical Trials for Mabpharm's Psoriasis Treatment	22-07-28	MT
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis	22-07-27	CI
Chinese Regulator Approves Mabpharm's Clinical Trial for New Drug	22-07-05	MT
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017	22-07-05	CI
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Mabpharm Limited

Equities

2181

KYG5780F1046

All News

Filters